Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16406071 | 1.00 | TSHR (0.47) | TSHRALOX5IDO1TACR1AGXT | |
| SCHEMBL17688149 | 1.00 | TSHR (0.47) | TSHRALOX5IDO1TACR1AGXT | |
| SCHEMBL24434511 | 0.86 | TSHR (0.50) | TSHRALOX5IDO1TACR1AGXT | |
| SCHEMBL1524101 | 0.79 | TSHR (0.67) | TSHRALOX5IDO1TACR1AGXT | |
| SCHEMBL1524098 | 0.79 | TSHR (0.67) | TSHRALOX5IDO1TACR1AGXT | |
| SCHEMBL1524411 | 0.79 | TSHR (0.67) | TSHRALOX5IDO1TACR1AGXT | |
| SCHEMBL8621499 | 0.79 | SLC1A1 (0.49) | TSHRALOX5IDO1TACR1 | |
| SCHEMBL2608898 | 0.77 | TSHR (0.48) | TSHRALOX5IDO1TACR1AGXT | |
| SCHEMBL11895684 | 0.77 | TSHR (0.48) | TSHRALOX5IDO1TACR1AGXT | |
| SCHEMBL11895687 | 0.77 | TSHR (0.48) | TSHRALOX5IDO1TACR1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240539-A1 | Preparation and Use of Cyclic Sulfonamide Derivatives as PAR-1 Receptor Antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3206687-A1 | PREPARATION AND USE OF CYCLIC SULFONAMIDE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2017-08-23 | — | — | EP | disclosed |
| WO-2016058144-A1 | PREPARATION AND USE OF CYCLIC SULFONAMIDE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2016060940-A1 | PREPARATION AND USE OF CYCLIC SULFONAMIDE DERIVATIVES AS PAR-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240539-A1 | Preparation and Use of Cyclic Sulfonamide Derivatives as PAR-1 Receptor Antagonists | F2R, PRSS1, F2RL1 | TSHR 473/4885ALOX5 1100/4885IDO1 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.